Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

June 30th 2025

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

Patient Fitness and the Doublet vs Triplet Debate in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how medical comorbidities, physiologic vs chronologic age, drug interactions, and performance status influence the choice between doublet and triplet therapy regimens.

Personalizing Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 30th 2025

Panelists discuss how clinical factors, including disease characteristics (Gleason score, volume, metastatic sites), patient factors (performance status, comorbidities, symptoms), and emerging genomic biomarkers, guide treatment intensification decisions in metastatic castration-sensitive prostate cancer.

FDA Approves Illuccix Gallium Ga-68 Gozetotide Injection for Pre-Taxane Radioligand Therapy in mCRPC

June 26th 2025

Gallium Ga-68 gozetotide injection is now indicated for use in PET imaging patient selection for radioligand therapy in the pre-taxane setting for mCRPC.

Dr Tagawa on the Evaluation of Lutetium Lu 177 Rospatamab Tetraxetan Plus SOC in mCRPC

June 23rd 2025

Scott T. Tagawa, MD, FASCO, FACP, MS, discusses the addition of lutetium 177Lu-rosopatamab tetraxetan to SOC in mCRPC.

Dr Morgans on HRQOL Outcomes With Darolutamide Plus ADT in mHSPC

June 23rd 2025

Alicia Morgans, MD, MPH, discusses health-related quality of life outcomes with darolutamide plus ADT in patients with mHSPC.

The OncFive: Top Oncology Articles for the Week of 6/15

June 21st 2025

Tafasitamab combination gets approval in follicular lymphoma, FDA declines to expand label for talazoparib plus enzalutamide in mCRPC, and more.

Darolutamide Plus ADT Earns Positive Opinion for European Approval From CHMP in Metastatic Hormone-Sensitive Prostate Cancer

June 20th 2025

The European Medicines Agency’s CHMP has recommended the approval of darolutamide plus ADT in mHSPC in the European Union.

FDA Declines to Expand Label for Talazoparib/Enzalutamide in mCRPC

June 17th 2025

The FDA declined to expand the label for talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer.

Dr McKay on Data for Olaparib Plus Radium-223 in CRPC With Bone Metastases

June 16th 2025

Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.

Darolutamide/ADT Combo Delays Pain Progression and Enhances QOL in mHSPC

June 11th 2025

Alicia Morgans, MD, MPH, discusses findings from a QOL analysis of the ARANOTE trial, which evaluated darolutamide plus ADT in patients with mHSPC.

Mayo Clinic Takes the Next Step in Making Heavy Particle Therapy Available in the Western Hemisphere for Patients with Aggressive Cancers

June 11th 2025

The Mayo Clinic's new facility will house the first carbon ion therapy program in the Western Hemisphere.

Olaparib Plus Radium-223 Doubles rPFS vs Radium-223 Alone in mCRPC

June 10th 2025

Rana R. McKay, MD, discusses data from the COMRADE trial, which showed that olaparib plus radium-223 improved rPFS in men with mCRPC with bone metastases.

The OncFive: Top Oncology Updates for the Week of 6/1

June 7th 2025

Revisit key updates from the ASCO Annual Meeting, the FDA, NCCN, and more.

Dr Saad on the FDA Approval of Darolutamide in mCSPC

June 4th 2025

Fred Saad, MD, discusses the FDA’s approval of darolutamide without chemotherapy for metastatic castration-sensitive prostate cancer

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC

June 3rd 2025

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

FDA Approves Darolutamide for Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

The FDA has approved darolutamide for the treatment of patients with metastatic castration-sensitive prostate cancer.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.